Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 41.46 7.35% 2.84
ONCE closed up 7.35 percent on Monday, December 10, 2018, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ONCE trend table...

Date Alert Name Type % Chg
Dec 10 Crossed Above 20 DMA Bullish 0.00%
Dec 10 Multiple of Ten Bullish Other 0.00%
Dec 10 Outside Day Range Expansion 0.00%
Dec 7 180 Bearish Setup Bearish Swing Setup 7.35%
Dec 7 Multiple of Ten Bearish Other 7.35%
Dec 4 Fell Below 20 DMA Bearish 5.90%
Dec 4 Multiple of Ten Bearish Other 5.90%
Dec 4 Down 3 Days in a Row Weakness 5.90%
Dec 4 Down 4 Days in a Row Weakness 5.90%
Dec 3 20 DMA Support Bullish -1.03%

Older signals for ONCE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 96.59
52 Week Low 35.63
Average Volume 637,302
200-Day Moving Average 64.7766
50-Day Moving Average 44.7926
20-Day Moving Average 40.69
10-Day Moving Average 41.045
Average True Range 2.7808
ADX 26.4
+DI 17.1337
-DI 21.252
Chandelier Exit (Long, 3 ATRs ) 37.8276
Chandelier Exit (Short, 3 ATRs ) 43.9724
Upper Bollinger Band 43.8472
Lower Bollinger Band 37.5328
Percent B (%b) 0.62
BandWidth 15.518309
MACD Line -1.3573
MACD Signal Line -1.6287
MACD Histogram 0.2715
Fundamentals Value
Market Cap 1.3 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -6.49
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.49
Resistance 3 (R3) 45.95 43.74 45.65
Resistance 2 (R2) 43.74 42.46 44.01 45.37
Resistance 1 (R1) 42.60 41.67 43.17 43.14 45.09
Pivot Point 40.39 40.39 40.68 40.66 40.39
Support 1 (S1) 39.25 39.11 39.82 39.79 37.83
Support 2 (S2) 37.04 38.32 37.31 37.55
Support 3 (S3) 35.90 37.04 37.27
Support 4 (S4) 36.44